DrugPatentWatch Database Preview
Kai Pharms Inc Company Profile
What is the competitive landscape for KAI PHARMS INC, and when can generic versions of KAI PHARMS INC drugs launch?
There are five US patents protecting KAI PHARMS INC drugs.
There are sixty patent family members on KAI PHARMS INC drugs in thirty-seven countries and six supplementary protection certificates in six countries.
Summary for Kai Pharms Inc
| International Patents: | 60 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Kai Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-002 | Feb 7, 2017 | RX | Yes | Yes | 9,701,712 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-001 | Feb 7, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-002 | Feb 7, 2017 | RX | Yes | Yes | 8,377,880 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | 9,701,712 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Kai Pharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,567,370 | Therapeutic agents for reducing parathyroid hormone levels | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Kai Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Lithuania | 3013318 | ➤ Sign Up |
| Hong Kong | 1222557 | ➤ Sign Up |
| European Patent Office | 3013318 | ➤ Sign Up |
| Japan | 2013155195 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Kai Pharms Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017 | Austria | ➤ Sign Up | PRODUCT NAME: ETELCALCETID ODER EIN SALZ DAVON EINSCHLIESSLICH ETELCALCETID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1142 (MITTEILUNG) 20161115 |
| 0864 | Netherlands | ➤ Sign Up | PRODUCT NAME: ETELCALCETIDE OF EEN ZOUT DAARVAN, MET INBEGRIP VAN ETELCALCETIDEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1142/001-012 20161115 |
| 0170006 00208 | Estonia | ➤ Sign Up | PRODUCT NAME: ETELKALTSETIID;REG NO/DATE: EU/1/16/1142 15.11.2016 |
| 2017000021 | Germany | ➤ Sign Up | PRODUCT NAME: ETELCALCETID ODER EIN SALZ DAVON, EINSCHLIESSLICH ETELCALCETIDHYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1142 20161111 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
